A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamaguchi, T, Kato, K, Yasui, H, Morizane, C, Ikeda, M, Ueno, H, Muro, K, Yamada, Y, Okusaka, T, Shirao, K, Shimada, Y, Nakahama, H, Matsumura, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360299/
https://www.ncbi.nlm.nih.gov/pubmed/17595665
http://dx.doi.org/10.1038/sj.bjc.6603855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360299/
https://www.ncbi.nlm.nih.gov/pubmed/17595665
http://dx.doi.org/10.1038/sj.bjc.6603855

Ejemplares similares